RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-4889

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation ; volume:9 ; number:6 ; day:22 ; month:5 ; year:2018 ; pages:1-13 ; date:6.2018
Cell death & disease ; 9, Heft 6 (22.5.2018), 1-13, 6.2018

Creator: Cho, Jung Hee

Contributor: You, Yeon-Mi
Yeom, Y I.
Lee, Dong Chul
Kim, Bo-Kyung
Won, Misun
Cho, Byoung Chul
Kang, Minho
Park, Seulki
Yang, Suk-Jin
Kim, Jang Seong
Kim, Jung-Ae
Park, Kyung Chan
SpringerLink (Online service)

DOI: 10.1038/s41419-018-0651-5

URN: urn:nbn:de:101:1-2018090400275856053167

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Cho, Jung Hee
You, Yeon-Mi
Yeom, Y I.
Lee, Dong Chul
Kim, Bo-Kyung
Won, Misun
Cho, Byoung Chul
Kang, Minho
Park, Seulki
Yang, Suk-Jin
Kim, Jang Seong
Kim, Jung-Ae
Park, Kyung Chan
SpringerLink (Online service)

Other Objects (12)

Inducing forgetting of unwanted memories through subliminal reactivation

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC – welche Bedeutung hat der EGF-R-Mutationsstatus?

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Inducing forgetting of unwanted memories through subliminal reactivation

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC – welche Bedeutung hat der EGF-R-Mutationsstatus?

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Inducing forgetting of unwanted memories through subliminal reactivation

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC – welche Bedeutung hat der EGF-R-Mutationsstatus?

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Inducing forgetting of unwanted memories through subliminal reactivation

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC – welche Bedeutung hat der EGF-R-Mutationsstatus?

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Inducing forgetting of unwanted memories through subliminal reactivation

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC – welche Bedeutung hat der EGF-R-Mutationsstatus?

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Inducing forgetting of unwanted memories through subliminal reactivation

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coatingGefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Aktueller Stellenwert von Erlotinib und Gefitinib in der palliativen Therapie des NSCLC – welche Bedeutung hat der EGF-R-Mutationsstatus?

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Related objects

Reset password